• Home
  • News & IR
  • News
Company News
DXVX·포항공대, 상온 보관 mRNA 플랫폼 상업권 계약
2024.12.17
Company News
DXVX·루카에이아이셀, 항바이러스 플랫폼 기술 공동연구
2024.12.16
Company News
Dx&Vx, 英 OVM으로부터 항암백신 'OVM-200' 도입 계약 체결
2024.12.12
Company News
디엑스앤브이엑스, JP모건헬스케어콘퍼런스 참가…
2024.12.05
Company News
디엑스앤브이엑스, 사업개발·글로벌 딜 전문가 윤명진 전무 영입
2024.11.19
Company News
디엑스앤브이엑스 "'MEDICA 2024'서 유럽시장 판로 모색"
2024.11.18
Company News
디엑스앤브이엑스 "'MEDICA 2024'서 유럽시장 판로 모색"
2024.11.18
Company News
디엑스앤브이엑스, mRNA 백신 한계 극복 기술 개발
2024.11.01
Company News
DXVX Develops Groundbreaking Technology to Overcome mRNA Vaccine Storage Limitations Verifies Possibility of Room-Temperature Storage for Over 10 Years Through Preliminary Research
2024.11.01
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8.   
  • 10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
  • Tel : 02-890-8700
  • IR Service : 02-6964-8770
  • Fax : 02-6964-8755

About Us

Goals & Promise

Leadership

Company History

IR

Notice & IR

Disclosure Information

Dx&Vx 2023 Award Impact

Contact

Private Policy Terms of Use twitter icon @dxvx_official
© 2024 Dx&Vx. All Rights Reserved.